Friday, July 10, 2026

pharma · Obese · Hyperlipemia

Suzhou Ribo Life

Suzhou Ribo Life clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Beijing, CN HQ
2007 Founded
32 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Beijing, CN
Founded
2007
Employees
32
Programs
4
Drugs
7
Patents
0
Intelligence · Clinical Programs

Suzhou Ribo Life projects

4 ClinicalTrials.gov programs sponsored by Suzhou Ribo Life.

Suzhou Ribo Life has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. SHR-A2009 ; Aumolertinib

    Suzhou Ribo Life Science Co.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  2. Dose escalation of SA030

    Suzhou Ribo Life Science Co.

    Obese

    phase 1 small molecule active

    1 trial
  3. RBD7022

    Suzhou Ribo Life Science Co.

    Hyperlipemia

    phase 1 small molecule completed

    1 trial
  4. UTAA91 injection

    Suzhou Ribo Life Science Co.

    Rheumatoid Arthritis (RA)

    phase 1 mab active

    1 trial

Frequently asked questions

How many clinical projects does Suzhou Ribo Life have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.